NSE: IPCALAB | BSE: 524494

Falling Comet

Download real time

1340.00 -14.40 (-1.06%)

27.38% Gain from 52W Low

360.4K NSE+BSE Volume

NSE 23 Jun, 2025 3:47 PM (IST)

33,996.4

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Ipca Laboratories Ltd.

11 Nov 2019

1340.00

-1.06%

RESULT REVIEW - IPCALAB

Buy: Ipca Laboratories Ltd.

Hem Securities

Ipca Laboratories Ltd is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. It is one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

08 Nov 2019

1340.00

-1.06%

Ipca Labs

Buy: Ipca Laboratories Ltd.

Target

Sharekhan

Ipca Laboratories Limited (Ipca) reported impressive results for Q2FY2020. Numbers were ahead of estimates. Aided by a strong double-digit growth across the formulations and API business, topline was up 29% y-oy to Rs 1284 crore. On the back of improved product mix and favorable raw material prices, operating profit jumped 52.5% y-o-y to Rs 263.5 cr while the adjusted PAT rose 62% y-o-y to Rs 193.5 cr. Expected traction across the formulation and API business, improved product mix and a substantial drop in the remedial cost are expected to...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

08 Nov 2019

1340.00

-1.06%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Securities Limited

Exports formulations (28% of FY19 revenue) grew on the back of growth in both international generics and international branded formulations. The international anti-malarial institutional business has also contributed substantially to overall exports growth. US traction will take more time than earlier estimated due to USFDA import alerts for the Ratlam facility that is the only API source for Silvassa and Pithampur formulations plants along with Silvassa and Pithampur (Indore) plants that are specifically earmarked for the US business, besides third party sales. However, a likely recovery...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

15 Aug 2019

1340.00

-1.06%

Earnings driven by API sales/better operating leverage; Ready for USFDA inspection

Buy: Ipca Laboratories Ltd.

Motilal Oswal

Healthy revenue growth across segments, except institutional anti-malaria business: Sales at INR10.8b (v/s est. INR9.6b) were up 23% YoY, led by API and exports (formulation). API grew 37% YoY to INR3b (30% of sales). Generics' exports grew 21% YoY to INR1.3b (13% of sales). Branded exports grew 17% YoY to INR916m (9% of sales). Domestic formulation sales grew 13% YoY to INR4.5b (46% of sales). Overall growth was dragged to some extent by 34% YoY decline in the Institutional (INR273m) segment. Better operating leverage offsets reduction in gross margins: Gross margins...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

14 Aug 2019

1340.00

-1.06%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.

Ipca Laboratories Ltd.

14 Aug 2019

1340.00

-1.06%

Q1FY20 Result Update

Accumulate: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Q1FY20 from its average contribution of 25%. This has resulted in higher material costs and lower gross margin by 360bps QoQ. Management guided that normalized gross margin will return from Q2FY20E onwards. The higher material costs also contributed from the higher price of material by 100bps out of 360bps in Q1FY20. IPCA is global leader in losartan production (Rs1.2bn sales in FY19) and its valsartan sales is improving from current run rate of Rs25m/month. It guided more than 20% growth in API sales in FY20E....

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

14 Aug 2019

1340.00

-1.06%

Ipca Labs

Buy: Ipca Laboratories Ltd.

Sharekhan

Ipca Laboratories Limited (Ipca) reported strong performance during the quarter. Sales for the quarter grew strongly by 23.2% y-o-y to Rs. 1,078 crore (16.9% above our estimate). Operating profit grew by 44.9% y-o-y to Rs. 207.9 crore (9.4% above our estimate). OPM improved by 289 BPS y-o-y to 19.3% (130 BPS below our estimate of 20.3%). Adjusted PAT reported growth of 50.4% y-o-y to Rs. 140.2 crore (16.8% above our estimate). Reported profit for the quarter grew by 88.1% y-o-y to Rs. 129.4 crore. Strong growth across domestic and exports (Formulation...

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.

Ipca Laboratories Ltd.

31 May 2019

1340.00

-1.06%

IPCA Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Securities Limited

Growth in exports formulations (28% of FY19 revenue) was on the back of growth in both international generics and international branded formulations. The international anti-malarial institutional business has also contributed substantially to overall exports growth. US traction will take more time than earlier estimated due to USFDA import alerts for the Ratlam facility that is the only API source for Silvassa and Pithampur formulations plants along with Silvassa and Pithampur (Indore) plants that are specifically earmarked for US business, besides third party sales. However, a likely...

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

31 May 2019

1340.00

-1.06%

IPCA Labs: Margin improvement due to product mix and lower overheads

Buy: Ipca Laboratories Ltd.

Target

Karvy

Margin improvement due to product mix and lower overheads: In Q4FY19, total revenues of IPCA Labs increased by 7%YoY to Rs 8338 mn (our estimates Rs 8706 mn) mainly due to increase in domestic formulations and API.

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

30 May 2019

1340.00

-1.06%

Cost headwinds receding; Generics/API outlook promising

Buy: Ipca Laboratories Ltd.

Motilal Oswal

Gross margin expanded 45bp YoY to 68% due to a better product mix. Reduced remediation cost (INR40m v/s INR100m in 4QFY18) and better operating leverage led to lower other expenses (-520bp YoY). As a result, EBITDA margin expanded at an even higher rate of 590bp YoY to 20.9% (our estimate: 17.4%). EBITDA was up 49% YoY at INR1.7b (our estimate: INR1.5b), while PAT increased 71% YoY to INR1b (our estimate: INR873m)....

Ipca Laboratories Ltd. is trading below all available SMAs

Is Ipca Laboratories Ltd. worth buying?

365 Votes:

Buy 80.27%

Sell 9.86%

Hold 9.86%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf